Cybin Initiates Dosing of CYB003 in Final Cohort of the P-II Trial for Major Depressive Disorder
Shots:
- The company initiated the dosing in cohort 6, the final cohort of the P-II study evaluating CYB003 in patients with major depressive disorder (MDD). The P-II efficacy results are expected in Q3/Q4’23 & dosing is expected to be completed in Q3’23
- The results showed that patients treated with CYB003 showed a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg
- Additionally, the first five cohorts of CYB003 administered at doses of 1/3/8/10/12mg have completed dosing with no serious AEs, and no patients discontinued due to AEs. CYB003, an investigational deuterated analog of psilocybin for the treatment of MDD
Ref: Businesswire | Image: Cybin
Related News:- Cybin Reports Dosing of First Two Patients in P-I/IIa Clinical Trial of CYB003 for the Treatment of Major Depressive Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
